← All drugs Report issue

gs-9256

Small moleculeexperimental

Clinical trial activity

2 trials · 1 clinical orgs · 0 marketing orgs

Phase 1

0

Phase 2

2

Phase 3

0

Phase 4

0

Earliest trial started Feb 1, 2010 (NCT01072695)

Timeline

2010s

Jan 1, 2010
Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

Hepatitis C virus NS3 protease/helicaseINHIBITOR
A3EZI9 inhibitor
- Genome polyprotein (A3EZI9) ↗
Genome polyproteinINHIBITOR
Genome polyprotein inhibitor
- Genome polyprotein ↗
Hepatitis C virus serine protease, NS3/NS4AINHIBITOR
Hepatitis C virus serine protease, NS3/NS4A inhibitor
- Non-structural protein 4A (NS4A) ↗
- Genome polyprotein (A3EZI9) ↗
- Hepatitis C virus NS4A protein
- Hepatitis C virus NS3 protease/helicase

Chemistry & pharmacology

Loading structure…

SMILES

COc1ccc2c(O[C@@H]3C[C@H]4C(=O)N[C@]5(P(=O)(O)Cc6c(F)cccc6F)C[C@H]5CCCCCCC[C@H](NC(=O)OC5CCCC5)C(=O)N4C3)cc(-c3csc(NC(C)C)n3)nc2c1Cl

Mol. weight: 957.48 g/mol
Lipinski Ro5: 3 violation(s)
Rule of 3: No
Chirality: Single Stereoisomer
Inorganic: No
Polymer: No

Oral

No

Parenteral

No

Topical

No

Sources

ChEMBLCHEMBL1956820 ↗

Also known as

gs-9256
gs-9256
gs-9256

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT01225380	Phase 2	Oct 1, 2010	Gilead Sciences
NCT01072695	Phase 2	Feb 1, 2010	Gilead Sciences

Showing 2 of 2 trials

Page 1 / 1

Organizations

Research & Development (1)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Gilead Sciences	For profit	2	2	1	2010

1 organizations

Page 1 / 1